The Innate Immune Response, Clinical Outcomes, and Ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF‐4878691) View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-03-30

AUTHORS

Fidock, BE Souberbielle, C Laxton, J Rawal, O Delpuech‐Adams, TP Corey, P Colman, V Kumar, JB Cheng, K Wright, S Srinivasan, K Rana, C Craig, N Horscroft, M Perros, M Westby, R Webster, E Ryst

ABSTRACT

Hepatitis C virus (HCV) infection is an issue of global concern, and studies are ongoing to identify new therapies that are both effective and safe. PF-4878691 is a Toll-like receptor 7 (TLR7) agonist modeled so as to dissociate its antiviral activities from its inflammatory activities. In a proof-of-mechanism study in healthy volunteers who received doses of 3, 6, and 9 mg of PF-4878691 twice a week for 2 weeks, PF-4878691 induced biomarkers of the immune and interferon (IFN) responses in a dose-dependent and dose-frequency-related manner. A novel finding was induction of TLR7 expression in vivo in response to PF-4878691, leading to an amplified biomarker response. A nonresponder at the 9-mg dose had a polymorphism in the IFN-α receptor 1 subunit (Val168Leu). Two subjects who had received 9-mg doses experienced serious adverse events (SAEs), characterized by flu-like symptoms, hypotension, and lymphopenia, leading to early termination of the study. TLR7 stimulation results in a pharmacologic response at levels commensurate with predicted antiviral efficacy, but these doses are associated with SAEs, raising concerns about the therapeutic window of this class of compounds for the treatment of HCV infection. More... »

PAGES

821-829

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/clpt.2011.60

DOI

http://dx.doi.org/10.1038/clpt.2011.60

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1049108856

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/21451504


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiviral Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepacivirus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunity, Innate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Toll-Like Receptor 7", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Pfizer Ltd Sandwich Research Laboratories Sandwich UK", 
          "id": "http://www.grid.ac/institutes/grid.418566.8", 
          "name": [
            "Pfizer Ltd Sandwich Research Laboratories Sandwich UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fidock", 
        "id": "sg:person.0672304424.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672304424.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Ltd Sandwich Research Laboratories Sandwich UK", 
          "id": "http://www.grid.ac/institutes/grid.418566.8", 
          "name": [
            "Pfizer Ltd Sandwich Research Laboratories Sandwich UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Souberbielle", 
        "givenName": "BE", 
        "id": "sg:person.01024105273.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024105273.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Ltd Sandwich Research Laboratories Sandwich UK", 
          "id": "http://www.grid.ac/institutes/grid.418566.8", 
          "name": [
            "Pfizer Ltd Sandwich Research Laboratories Sandwich UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Laxton", 
        "givenName": "C", 
        "id": "sg:person.01304473075.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304473075.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Ltd Sandwich Research Laboratories Sandwich UK", 
          "id": "http://www.grid.ac/institutes/grid.418566.8", 
          "name": [
            "Pfizer Ltd Sandwich Research Laboratories Sandwich UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rawal", 
        "givenName": "J", 
        "id": "sg:person.01174442643.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174442643.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Ltd Sandwich Research Laboratories Sandwich UK", 
          "id": "http://www.grid.ac/institutes/grid.418566.8", 
          "name": [
            "Pfizer Ltd Sandwich Research Laboratories Sandwich UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Delpuech\u2010Adams", 
        "givenName": "O", 
        "id": "sg:person.0713054131.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0713054131.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Ltd Sandwich Research Laboratories Sandwich UK", 
          "id": "http://www.grid.ac/institutes/grid.418566.8", 
          "name": [
            "Pfizer Ltd Sandwich Research Laboratories Sandwich UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Corey", 
        "givenName": "TP", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Ltd Sandwich Research Laboratories Sandwich UK", 
          "id": "http://www.grid.ac/institutes/grid.418566.8", 
          "name": [
            "Pfizer Ltd Sandwich Research Laboratories Sandwich UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Colman", 
        "givenName": "P", 
        "id": "sg:person.01170244475.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170244475.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc Groton Research Laboratories Groton Connecticut USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc Groton Research Laboratories Groton Connecticut USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kumar", 
        "givenName": "V", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc Groton Research Laboratories Groton Connecticut USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc Groton Research Laboratories Groton Connecticut USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cheng", 
        "givenName": "JB", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc Groton Research Laboratories Groton Connecticut USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc Groton Research Laboratories Groton Connecticut USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wright", 
        "givenName": "K", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc Specialty Care Business Unit New London Connecticut USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc Specialty Care Business Unit New London Connecticut USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Srinivasan", 
        "givenName": "S", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc Specialty Care Business Unit New London Connecticut USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc Specialty Care Business Unit New London Connecticut USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rana", 
        "givenName": "K", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Ltd Sandwich Research Laboratories Sandwich UK", 
          "id": "http://www.grid.ac/institutes/grid.418566.8", 
          "name": [
            "Pfizer Ltd Sandwich Research Laboratories Sandwich UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Craig", 
        "givenName": "C", 
        "id": "sg:person.01360103362.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01360103362.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Ltd Sandwich Research Laboratories Sandwich UK", 
          "id": "http://www.grid.ac/institutes/grid.418566.8", 
          "name": [
            "Pfizer Ltd Sandwich Research Laboratories Sandwich UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Horscroft", 
        "givenName": "N", 
        "id": "sg:person.01230020510.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230020510.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca Pharmaceuticals Boston Massachusetts USA", 
          "id": "http://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "Pfizer Ltd Sandwich Research Laboratories Sandwich UK", 
            "AstraZeneca Pharmaceuticals Boston Massachusetts USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Perros", 
        "givenName": "M", 
        "id": "sg:person.01271653754.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271653754.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Ltd Sandwich Research Laboratories Sandwich UK", 
          "id": "http://www.grid.ac/institutes/grid.418566.8", 
          "name": [
            "Pfizer Ltd Sandwich Research Laboratories Sandwich UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Westby", 
        "givenName": "M", 
        "id": "sg:person.01315031425.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315031425.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Ltd Sandwich Research Laboratories Sandwich UK", 
          "id": "http://www.grid.ac/institutes/grid.418566.8", 
          "name": [
            "Pfizer Ltd Sandwich Research Laboratories Sandwich UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Webster", 
        "givenName": "R", 
        "id": "sg:person.0773406171.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773406171.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Ltd Sandwich Research Laboratories Sandwich UK", 
          "id": "http://www.grid.ac/institutes/grid.418566.8", 
          "name": [
            "Pfizer Ltd Sandwich Research Laboratories Sandwich UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ryst", 
        "givenName": "E", 
        "id": "sg:person.013453667620.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013453667620.00"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00262-010-0914-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036706478", 
          "https://doi.org/10.1007/s00262-010-0914-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature04606", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025841493", 
          "https://doi.org/10.1038/nature04606"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm0310-265", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039673545", 
          "https://doi.org/10.1038/nm0310-265"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2172-8-26", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027972907", 
          "https://doi.org/10.1186/1471-2172-8-26"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.clpt.6100394", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048216647", 
          "https://doi.org/10.1038/sj.clpt.6100394"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-03-30", 
    "datePublishedReg": "2011-03-30", 
    "description": "Hepatitis C virus (HCV) infection is an issue of global concern, and studies are ongoing to identify new therapies that are both effective and safe. PF-4878691 is a Toll-like receptor 7 (TLR7) agonist modeled so as to dissociate its antiviral activities from its inflammatory activities. In a proof-of-mechanism study in healthy volunteers who received doses of 3, 6, and 9 mg of PF-4878691 twice a week for 2 weeks, PF-4878691 induced biomarkers of the immune and interferon (IFN) responses in a dose-dependent and dose-frequency-related manner. A novel finding was induction of TLR7 expression in vivo in response to PF-4878691, leading to an amplified biomarker response. A nonresponder at the 9-mg dose had a polymorphism in the IFN-\u03b1 receptor 1 subunit (Val168Leu). Two subjects who had received 9-mg doses experienced serious adverse events (SAEs), characterized by flu-like symptoms, hypotension, and lymphopenia, leading to early termination of the study. TLR7 stimulation results in a pharmacologic response at levels commensurate with predicted antiviral efficacy, but these doses are associated with SAEs, raising concerns about the therapeutic window of this class of compounds for the treatment of HCV infection.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/clpt.2011.60", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1017409", 
        "issn": [
          "0009-9236", 
          "1532-6535"
        ], 
        "name": "Clinical Pharmacology & Therapeutics", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "89"
      }
    ], 
    "keywords": [
      "serious adverse events", 
      "antiviral efficacy", 
      "Toll-like receptor 7 agonist", 
      "hepatitis C virus infection", 
      "receptor 7 agonist", 
      "flu-like symptoms", 
      "innate immune response", 
      "receptor 1 subunit", 
      "TLR7 expression", 
      "HCV infection", 
      "adverse events", 
      "TLR7 agonist", 
      "inflammatory activity", 
      "clinical outcomes", 
      "virus infection", 
      "immune response", 
      "healthy volunteers", 
      "new therapies", 
      "therapeutic window", 
      "pharmacologic response", 
      "antiviral activity", 
      "interferon response", 
      "doses", 
      "novel findings", 
      "agonists", 
      "stimulation results", 
      "infection", 
      "weeks", 
      "efficacy", 
      "early termination", 
      "response", 
      "hypotension", 
      "nonresponders", 
      "lymphopenia", 
      "biomarker responses", 
      "IFN", 
      "therapy", 
      "symptoms", 
      "class of compounds", 
      "dose", 
      "Immune", 
      "study", 
      "volunteers", 
      "biomarkers", 
      "outcomes", 
      "treatment", 
      "activity", 
      "vivo", 
      "induction", 
      "subjects", 
      "mechanism study", 
      "polymorphism", 
      "global concern", 
      "expression", 
      "findings", 
      "concern", 
      "levels", 
      "termination", 
      "events", 
      "manner", 
      "subunits", 
      "results", 
      "compounds", 
      "window", 
      "issues", 
      "class", 
      "proof", 
      "C virus (HCV) infection", 
      "PF-4878691", 
      "PF-4878691 induced biomarkers", 
      "induced biomarkers", 
      "TLR7 stimulation results", 
      "Ex Vivo HCV Antiviral Efficacy", 
      "Vivo HCV Antiviral Efficacy", 
      "HCV Antiviral Efficacy"
    ], 
    "name": "The Innate Immune Response, Clinical Outcomes, and Ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF\u20104878691)", 
    "pagination": "821-829", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1049108856"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/clpt.2011.60"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "21451504"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/clpt.2011.60", 
      "https://app.dimensions.ai/details/publication/pub.1049108856"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_531.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/clpt.2011.60"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/clpt.2011.60'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/clpt.2011.60'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/clpt.2011.60'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/clpt.2011.60'


 

This table displays all metadata directly associated to this object as RDF triples.

334 TRIPLES      22 PREDICATES      120 URIs      106 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/clpt.2011.60 schema:about N08a84809781440bdaea0dce1732b26ab
2 N0af5dd8e5faf4dfcb17396f478730cd6
3 N1826ee2103a74887bef54b973a2e7222
4 N5841e3ce9b3e4943822b46c3f73bf75d
5 N5bc3b63c33c1495c88796a308f5bd6b4
6 N5cc7ca9f56c54e3880d0955a2750e304
7 N6e95733468ba49e2ac7f2336a515efa7
8 N853d94e2a3d045249084b771dcbb497e
9 N91081da9cbc340d0ac9438eadcbe5790
10 N996d83981631437a8f7d0c467246ec6a
11 Nb176a36ac8e541c8aecdeb93b958b67c
12 Nbcb531f88d19414997a8c48978edcdb1
13 Nc9002282287b4af89a991abbde5802a9
14 anzsrc-for:11
15 anzsrc-for:1103
16 anzsrc-for:1107
17 schema:author N0e2d44ec3c044a1a8b452a0cdda7b23a
18 schema:citation sg:pub.10.1007/s00262-010-0914-1
19 sg:pub.10.1038/nature04606
20 sg:pub.10.1038/nm0310-265
21 sg:pub.10.1038/sj.clpt.6100394
22 sg:pub.10.1186/1471-2172-8-26
23 schema:datePublished 2011-03-30
24 schema:datePublishedReg 2011-03-30
25 schema:description Hepatitis C virus (HCV) infection is an issue of global concern, and studies are ongoing to identify new therapies that are both effective and safe. PF-4878691 is a Toll-like receptor 7 (TLR7) agonist modeled so as to dissociate its antiviral activities from its inflammatory activities. In a proof-of-mechanism study in healthy volunteers who received doses of 3, 6, and 9 mg of PF-4878691 twice a week for 2 weeks, PF-4878691 induced biomarkers of the immune and interferon (IFN) responses in a dose-dependent and dose-frequency-related manner. A novel finding was induction of TLR7 expression in vivo in response to PF-4878691, leading to an amplified biomarker response. A nonresponder at the 9-mg dose had a polymorphism in the IFN-α receptor 1 subunit (Val168Leu). Two subjects who had received 9-mg doses experienced serious adverse events (SAEs), characterized by flu-like symptoms, hypotension, and lymphopenia, leading to early termination of the study. TLR7 stimulation results in a pharmacologic response at levels commensurate with predicted antiviral efficacy, but these doses are associated with SAEs, raising concerns about the therapeutic window of this class of compounds for the treatment of HCV infection.
26 schema:genre article
27 schema:inLanguage en
28 schema:isAccessibleForFree false
29 schema:isPartOf N012c1d19828a46dab56b5c509bffcaef
30 Nc7816f2004b4444e84d25b161c0d85f1
31 sg:journal.1017409
32 schema:keywords C virus (HCV) infection
33 Ex Vivo HCV Antiviral Efficacy
34 HCV Antiviral Efficacy
35 HCV infection
36 IFN
37 Immune
38 PF-4878691
39 PF-4878691 induced biomarkers
40 TLR7 agonist
41 TLR7 expression
42 TLR7 stimulation results
43 Toll-like receptor 7 agonist
44 Vivo HCV Antiviral Efficacy
45 activity
46 adverse events
47 agonists
48 antiviral activity
49 antiviral efficacy
50 biomarker responses
51 biomarkers
52 class
53 class of compounds
54 clinical outcomes
55 compounds
56 concern
57 dose
58 doses
59 early termination
60 efficacy
61 events
62 expression
63 findings
64 flu-like symptoms
65 global concern
66 healthy volunteers
67 hepatitis C virus infection
68 hypotension
69 immune response
70 induced biomarkers
71 induction
72 infection
73 inflammatory activity
74 innate immune response
75 interferon response
76 issues
77 levels
78 lymphopenia
79 manner
80 mechanism study
81 new therapies
82 nonresponders
83 novel findings
84 outcomes
85 pharmacologic response
86 polymorphism
87 proof
88 receptor 1 subunit
89 receptor 7 agonist
90 response
91 results
92 serious adverse events
93 stimulation results
94 study
95 subjects
96 subunits
97 symptoms
98 termination
99 therapeutic window
100 therapy
101 treatment
102 virus infection
103 vivo
104 volunteers
105 weeks
106 window
107 schema:name The Innate Immune Response, Clinical Outcomes, and Ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF‐4878691)
108 schema:pagination 821-829
109 schema:productId N902c64c0907f4cecadc5021b8e03fd1b
110 Na4b9d847277d489db4100f295847e1ae
111 Ne7fa1539a7aa43d1914a9587184b35a1
112 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049108856
113 https://doi.org/10.1038/clpt.2011.60
114 schema:sdDatePublished 2022-01-01T18:24
115 schema:sdLicense https://scigraph.springernature.com/explorer/license/
116 schema:sdPublisher Nd80be9e8fec14821a73c868adf1c62a5
117 schema:url https://doi.org/10.1038/clpt.2011.60
118 sgo:license sg:explorer/license/
119 sgo:sdDataset articles
120 rdf:type schema:ScholarlyArticle
121 N009989959d204758a3c8a8a08066754b schema:affiliation grid-institutes:grid.410513.2
122 schema:familyName Srinivasan
123 schema:givenName S
124 rdf:type schema:Person
125 N012c1d19828a46dab56b5c509bffcaef schema:volumeNumber 89
126 rdf:type schema:PublicationVolume
127 N02ff6aaab4d6467e990baa627564f0ff rdf:first sg:person.01360103362.27
128 rdf:rest N5954728cc3994456baee7e16ec2da0e8
129 N058c8b77c10f4db3a1b95ff1089ab3e5 rdf:first sg:person.01174442643.59
130 rdf:rest Nf9634e62dcb84541835e240c2cc72744
131 N08a84809781440bdaea0dce1732b26ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Young Adult
133 rdf:type schema:DefinedTerm
134 N0af5dd8e5faf4dfcb17396f478730cd6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Toll-Like Receptor 7
136 rdf:type schema:DefinedTerm
137 N0e2d44ec3c044a1a8b452a0cdda7b23a rdf:first sg:person.0672304424.03
138 rdf:rest Nd3decd86179a45d2b7f6fb9b43ea3d8e
139 N114e3fa2cf2e48db898af5592f2a8d67 rdf:first sg:person.01304473075.24
140 rdf:rest N058c8b77c10f4db3a1b95ff1089ab3e5
141 N1826ee2103a74887bef54b973a2e7222 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Cohort Studies
143 rdf:type schema:DefinedTerm
144 N20068aa517964c349009ae2fc7748abd schema:affiliation grid-institutes:grid.410513.2
145 schema:familyName Wright
146 schema:givenName K
147 rdf:type schema:Person
148 N250dd181b2ea4ae691534cb0f61e15bd rdf:first N009989959d204758a3c8a8a08066754b
149 rdf:rest Nbcd3629710d542adb9c9a9becb997f7b
150 N49d83a3e50ba42cab5579d91d34bcee0 rdf:first N20068aa517964c349009ae2fc7748abd
151 rdf:rest N250dd181b2ea4ae691534cb0f61e15bd
152 N55ac54be0a324283b44f12fb56087b80 rdf:first sg:person.01315031425.05
153 rdf:rest Nf3e1079838ae4713bcc70dcdf3834989
154 N5841e3ce9b3e4943822b46c3f73bf75d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Treatment Outcome
156 rdf:type schema:DefinedTerm
157 N5954728cc3994456baee7e16ec2da0e8 rdf:first sg:person.01230020510.79
158 rdf:rest N93de5ddba6fc4efaaf2b75e7eed234fc
159 N5ba39289699345b2b6c395e3191455fa rdf:first Ne57904f6b9284b4b8435406af4a2d7c8
160 rdf:rest N49d83a3e50ba42cab5579d91d34bcee0
161 N5bc3b63c33c1495c88796a308f5bd6b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Dose-Response Relationship, Drug
163 rdf:type schema:DefinedTerm
164 N5cc7ca9f56c54e3880d0955a2750e304 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Antiviral Agents
166 rdf:type schema:DefinedTerm
167 N5fc194a4e9d84619886d0f415a3a3a3c rdf:first Ne706fd2b1b064971b6f3018a05987023
168 rdf:rest N5ba39289699345b2b6c395e3191455fa
169 N660846d76ba94192a10e8718247deffb rdf:first sg:person.013453667620.00
170 rdf:rest rdf:nil
171 N6e95733468ba49e2ac7f2336a515efa7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Humans
173 rdf:type schema:DefinedTerm
174 N75e7a80179c14f36bbfaefdbca9dea71 rdf:first sg:person.01170244475.16
175 rdf:rest N5fc194a4e9d84619886d0f415a3a3a3c
176 N853d94e2a3d045249084b771dcbb497e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Immunity, Innate
178 rdf:type schema:DefinedTerm
179 N888fcbb4d8d5453fb74929fe7679dc5a rdf:first Ndf9ade65806d49148c246ccf709bce07
180 rdf:rest N75e7a80179c14f36bbfaefdbca9dea71
181 N902c64c0907f4cecadc5021b8e03fd1b schema:name doi
182 schema:value 10.1038/clpt.2011.60
183 rdf:type schema:PropertyValue
184 N91081da9cbc340d0ac9438eadcbe5790 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Adult
186 rdf:type schema:DefinedTerm
187 N93de5ddba6fc4efaaf2b75e7eed234fc rdf:first sg:person.01271653754.33
188 rdf:rest N55ac54be0a324283b44f12fb56087b80
189 N996d83981631437a8f7d0c467246ec6a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Male
191 rdf:type schema:DefinedTerm
192 Na4b9d847277d489db4100f295847e1ae schema:name pubmed_id
193 schema:value 21451504
194 rdf:type schema:PropertyValue
195 Nb176a36ac8e541c8aecdeb93b958b67c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Middle Aged
197 rdf:type schema:DefinedTerm
198 Nbcb531f88d19414997a8c48978edcdb1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Female
200 rdf:type schema:DefinedTerm
201 Nbcd3629710d542adb9c9a9becb997f7b rdf:first Nfaa471f7d6ed429b9d0f97db553673eb
202 rdf:rest N02ff6aaab4d6467e990baa627564f0ff
203 Nc7816f2004b4444e84d25b161c0d85f1 schema:issueNumber 6
204 rdf:type schema:PublicationIssue
205 Nc9002282287b4af89a991abbde5802a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Hepacivirus
207 rdf:type schema:DefinedTerm
208 Nd3decd86179a45d2b7f6fb9b43ea3d8e rdf:first sg:person.01024105273.83
209 rdf:rest N114e3fa2cf2e48db898af5592f2a8d67
210 Nd80be9e8fec14821a73c868adf1c62a5 schema:name Springer Nature - SN SciGraph project
211 rdf:type schema:Organization
212 Ndf9ade65806d49148c246ccf709bce07 schema:affiliation grid-institutes:grid.418566.8
213 schema:familyName Corey
214 schema:givenName TP
215 rdf:type schema:Person
216 Ne57904f6b9284b4b8435406af4a2d7c8 schema:affiliation grid-institutes:grid.410513.2
217 schema:familyName Cheng
218 schema:givenName JB
219 rdf:type schema:Person
220 Ne706fd2b1b064971b6f3018a05987023 schema:affiliation grid-institutes:grid.410513.2
221 schema:familyName Kumar
222 schema:givenName V
223 rdf:type schema:Person
224 Ne7fa1539a7aa43d1914a9587184b35a1 schema:name dimensions_id
225 schema:value pub.1049108856
226 rdf:type schema:PropertyValue
227 Nf3e1079838ae4713bcc70dcdf3834989 rdf:first sg:person.0773406171.27
228 rdf:rest N660846d76ba94192a10e8718247deffb
229 Nf9634e62dcb84541835e240c2cc72744 rdf:first sg:person.0713054131.33
230 rdf:rest N888fcbb4d8d5453fb74929fe7679dc5a
231 Nfaa471f7d6ed429b9d0f97db553673eb schema:affiliation grid-institutes:grid.410513.2
232 schema:familyName Rana
233 schema:givenName K
234 rdf:type schema:Person
235 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
236 schema:name Medical and Health Sciences
237 rdf:type schema:DefinedTerm
238 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
239 schema:name Clinical Sciences
240 rdf:type schema:DefinedTerm
241 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
242 schema:name Immunology
243 rdf:type schema:DefinedTerm
244 sg:journal.1017409 schema:issn 0009-9236
245 1532-6535
246 schema:name Clinical Pharmacology & Therapeutics
247 schema:publisher Springer Nature
248 rdf:type schema:Periodical
249 sg:person.01024105273.83 schema:affiliation grid-institutes:grid.418566.8
250 schema:familyName Souberbielle
251 schema:givenName BE
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024105273.83
253 rdf:type schema:Person
254 sg:person.01170244475.16 schema:affiliation grid-institutes:grid.418566.8
255 schema:familyName Colman
256 schema:givenName P
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170244475.16
258 rdf:type schema:Person
259 sg:person.01174442643.59 schema:affiliation grid-institutes:grid.418566.8
260 schema:familyName Rawal
261 schema:givenName J
262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174442643.59
263 rdf:type schema:Person
264 sg:person.01230020510.79 schema:affiliation grid-institutes:grid.418566.8
265 schema:familyName Horscroft
266 schema:givenName N
267 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230020510.79
268 rdf:type schema:Person
269 sg:person.01271653754.33 schema:affiliation grid-institutes:grid.418152.b
270 schema:familyName Perros
271 schema:givenName M
272 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271653754.33
273 rdf:type schema:Person
274 sg:person.01304473075.24 schema:affiliation grid-institutes:grid.418566.8
275 schema:familyName Laxton
276 schema:givenName C
277 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304473075.24
278 rdf:type schema:Person
279 sg:person.01315031425.05 schema:affiliation grid-institutes:grid.418566.8
280 schema:familyName Westby
281 schema:givenName M
282 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315031425.05
283 rdf:type schema:Person
284 sg:person.013453667620.00 schema:affiliation grid-institutes:grid.418566.8
285 schema:familyName Ryst
286 schema:givenName E
287 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013453667620.00
288 rdf:type schema:Person
289 sg:person.01360103362.27 schema:affiliation grid-institutes:grid.418566.8
290 schema:familyName Craig
291 schema:givenName C
292 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01360103362.27
293 rdf:type schema:Person
294 sg:person.0672304424.03 schema:affiliation grid-institutes:grid.418566.8
295 schema:familyName Fidock
296 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672304424.03
297 rdf:type schema:Person
298 sg:person.0713054131.33 schema:affiliation grid-institutes:grid.418566.8
299 schema:familyName Delpuech‐Adams
300 schema:givenName O
301 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0713054131.33
302 rdf:type schema:Person
303 sg:person.0773406171.27 schema:affiliation grid-institutes:grid.418566.8
304 schema:familyName Webster
305 schema:givenName R
306 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773406171.27
307 rdf:type schema:Person
308 sg:pub.10.1007/s00262-010-0914-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036706478
309 https://doi.org/10.1007/s00262-010-0914-1
310 rdf:type schema:CreativeWork
311 sg:pub.10.1038/nature04606 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025841493
312 https://doi.org/10.1038/nature04606
313 rdf:type schema:CreativeWork
314 sg:pub.10.1038/nm0310-265 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039673545
315 https://doi.org/10.1038/nm0310-265
316 rdf:type schema:CreativeWork
317 sg:pub.10.1038/sj.clpt.6100394 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048216647
318 https://doi.org/10.1038/sj.clpt.6100394
319 rdf:type schema:CreativeWork
320 sg:pub.10.1186/1471-2172-8-26 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027972907
321 https://doi.org/10.1186/1471-2172-8-26
322 rdf:type schema:CreativeWork
323 grid-institutes:grid.410513.2 schema:alternateName Pfizer Inc Groton Research Laboratories Groton Connecticut USA
324 Pfizer Inc Specialty Care Business Unit New London Connecticut USA
325 schema:name Pfizer Inc Groton Research Laboratories Groton Connecticut USA
326 Pfizer Inc Specialty Care Business Unit New London Connecticut USA
327 rdf:type schema:Organization
328 grid-institutes:grid.418152.b schema:alternateName AstraZeneca Pharmaceuticals Boston Massachusetts USA
329 schema:name AstraZeneca Pharmaceuticals Boston Massachusetts USA
330 Pfizer Ltd Sandwich Research Laboratories Sandwich UK
331 rdf:type schema:Organization
332 grid-institutes:grid.418566.8 schema:alternateName Pfizer Ltd Sandwich Research Laboratories Sandwich UK
333 schema:name Pfizer Ltd Sandwich Research Laboratories Sandwich UK
334 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...